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Introduction
Osteoporosis is a skeletal disorder characterised by compro-
mised bone strength predisposing a person to an increased risk 
of fracture. The current reference standard for the diagnosis of 
osteoporosis is the measurement of bone mineral density 
(BMD) using dual-energy X-ray absorptiometry (DXA). 
Although low BMD is among the strongest known risk factors 
for fragility fractures, it is not robust.1,2 For example, in the 
Rotterdam Study, only 44% of the women and 21% of the men 
with a non-vertebral fracture had a BMD below the threshold 
for osteoporosis.1 To improve its predictive performance, there 
has been a trend towards the use of clinical risk factors (CRFs) 
in combination with BMD measurements.3 One such clinically 
accepted risk calculator is the Fracture Risk Assessment Tool 
(FRAX).4 Although the use of FRAX may be an advance over 
BMD alone, there is still room for improvement. In a recent 
systematic review and meta-analysis on the performance of 
FRAX in predicting 10-year risk of major osteoporotic frac-
tures, a substantial number of patients who developed fractures 
were missed by the baseline FRAX assessment.5 Furthermore, 
FRAX includes BMD as an input in predicting fracture risk, 
and assessment of BMD by DXA or other instruments requires 
direct patient measurement by highly trained staff and regular 
equipment calibration, making it unsuitable for widespread use. 
With an anticipated rising worldwide population burden of 
osteoporosis and fragility fractures,6 the World Health 
Organization has identified a need for improved prognostic 
indicators and alternatives to BMD-based diagnostic tools to 
assess fracture risk.7,8 The ideal test for bone fragility would be 
amenable to high sample throughput operation in clinical refer-
ence labs and would work in conjunction with known CRFs to 
enable the screening of a broader population base and aid pre-
ventative treatment decisions. Such a test that is capable of 
accurately assessing long-term fracture risk would be a signifi-
cant advance in osteoporosis diagnosis and fracture prevention.
The use of nail tissue, rather than bone, could possibly pro-
vide a simpler means of assessing fracture risk. Previous studies 
by the authors have hypothesised a relationship between 
human nail structure, osteoporosis, and fracture risk9–14 due to 
common exposure to systemic factors for bone and nail. These 
studies have used Raman spectroscopy, an optical analytical 
technique for obtaining semi-quantitative and qualitative 
information on complex samples. The spectrum of a sample is 
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a linear combination of the spectra of all the molecules in the 
sample and can be regarded as an optical molecular fingerprint 
of the sample.15 Keratin and type I collagen are the 2 key pro-
teins in nail and bone, respectively, and they both undergo 
post-translational modifications, which can be identified using 
Raman spectroscopy.16–18 Recently, these 2 proteins as meas-
ured in the bone and claw of rats have been shown to exhibit 
parallel disordering under systemic changes induced by loss of 
ovaries.19 In humans, loss of ovaries leads to a decline in oestro-
gen production (and therefore systemic circulation) is promi-
nent and is associated with increased fracture risk.20 In our 
most recently published clinical study, Fracture Risk Assessment 
by Nail (FRAN), nail clippings were sourced from 633 post-
menopausal British and Irish women from 6 clinical sites, of 
whom 42% had experienced a fragility fracture.13 Results from 
the test set showed that a novel algorithm, combining spectros-
copy data with clinical data, provided area under the curve 
(AUC) of 74% compared with an AUC of 62% from a reduced 
QFracture Score21,22 (a clinically accepted risk calculator, simi-
lar but not identical to FRAX) and 60% from the DXA T 
score. Spectroscopic interpretation revealed that the test was 
discriminating those at risk of fracture based on a pattern of 
differences in amino acid composition and concomitant differ-
ences in the higher levels (secondary to quaternary) of structure 
of the keratin protein.14 As promising as the outcomes of this 
study were, it was not designed to test the predictive ability of 
the tool.
The study reported here was designed as a preliminary pro-
spective test to understand the prospects of using Raman spec-
troscopic measurement of nails to predict risk of future fracture. 
The objective was to assess the ability of Raman spectroscopic 
analysis of nail samples in post-menopausal women less than 
65 years to discriminate between those who have and have not 
suffered a hip fracture over a time period up to 20 years after 
sample collection in a nested case-control study. The nail sam-
ples were sourced as matched case-control pairs from those 
archived in the Nurses’ Health Study (NHS), a long-term 
cohort study of women. Alongside testing the prospective 
power of Raman spectroscopy to identify those who would go 
on to suffer a hip fracture, the study also explored whether 
superior performance could be obtained with the Raman-based 
result in combination with CRFs over the CRFs alone.
Methods
Nurses’ Health Study
The NHS is a cohort study which commenced in 1976 with 
121 700 female registered nurses aged between 30 and 55 years 
and living in one of the 11 most populous US states. 
Approximately 96% of the participants are white. The women 
have been followed up by questionnaire every 2 years. The CRF 
data from the biennial questionnaire immediately prior to toe-
nail collection that are part of FRAX include race, smoking 
status, weight and height (from which body mass index [BMI] 
was calculated), thyroid hormone use, rheumatoid arthritis, 
diabetes, wrist fracture, osteoporosis diagnosed by a physician, 
age at menopause, and alcohol consumption. Information on 
femoral neck BMD and other FRAX CRFs, ie, glucocorticoid 
use, parental history of hip fracture, and some secondary causes 
of osteoporosis, were not available. Diagnoses of stroke and 
cancer and use of post-menopausal hormones were also 
assessed and used to identify the study population.
With respect to hip fracture outcomes, the women were 
asked to report all previous fractures in 1982 and subsequent 
fractures were recorded on later questionnaires. Report of hip 
fracture can be expected to be accurate in a population of 
trained nurses. Validity was examined in a 1986 study that con-
firmed in 30 reports of hip fracture that were all present in the 
medical records.23 A number of studies focused on hip fracture 
risk have already been conducted in this cohort and have shown 
that activity, BMI, and vitamin D are associated with lower risk 
and that abdominal obesity is associated with higher risk.24–27
Archived toenail clippings
Toenail clippings were collected from 62 865 participants in 
the NHS cohort between December 1982 and July 1984 when 
the participants were between 36 and 63 years of age 
(median = 48.9). Participants were asked to send clippings from 
all 10 toenails. The clippings were stored in dust and lightproof 
envelopes in a dry environment at room temperature following 
collection. The nails were originally collected to investigate the 
relationship between selenium levels in the nail and cancer 
risk28,29 and have since been used in a number of published 
studies.30,31 The toenail samples used in these investigations 
were often destroyed in processing; therefore, 49 820 samples 
remained in storage.
Study population and design
A nested case-control design was selected to establish the abil-
ity of the Raman-based analysis to differentiate between 
women with a history of hip fracture and control subjects. The 
study population from which the sample was drawn consisted 
of the women who, at the time of their toenail return, were 
post-menopausal, aged 50 to 63 years, not currently using post-
menopausal hormones, and without a hip fracture, stroke, or 
cancer history (n = 13 312). From this population, we identified 
279 cases who had a hip fracture from 3 to 20 years after toe-
nail return (median = 14.5 years). Hip fractures due to trau-
matic events (eg, motor vehicle accident, skiing, horse riding) 
were excluded. Of the remaining women in the study popula-
tion who did not report a hip fracture through 2004, we ran-
domly selected 1 control per case matched on month and year 
of birth.
For this study in which we developed the Raman analytic 
algorithm, we randomly selected 82 case-control pairs from the 
available 279 pairs to ensure that we would have sufficient 
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remaining toenails for a later validation study. One sample 
envelope proved to be empty; therefore, 163 samples were 
available for analysis. Approval for the study was obtained from 
the Institutional Review Board of the Brigham and Women’s 
Hospital. The subjects provided informed consent when the 
nail samples were collected, and the study was conducted in 
accordance with the Declaration of Helsinki.
Nail spectral measurement and processing
The instrumentation used was a Sierra Reader (Snowy Range 
Instruments, Laramie, WY, USA) using 785-nm excitation 
with 50 mW power at the sample. Measurements were con-
ducted by 3 operators blind to clinical details, based at one 
location (C-TRIC, Altnagelvin Hospital, Londonderry, UK), 
and using one instrument. Triplicate, spatially separated meas-
urements, each lasting 1 minute, were conducted on each sam-
ple. The nails were inspected by the naked eye to confirm that 
they were free of visible contamination, then the nails were 
placed so that the upper surface of the nail faced the laser exit 
aperture. No further sample preparation was undertaken. The 
Raman data collected from the nails were processed using 
models created in a previous study.13 Briefly, this was a singu-
lar-value decomposition–based background removal32–34 mod-
elled on an archive of 1500 nails (excluding all nails used in test 
set for this study), with linear interpolation of the loadings 
using 12 points. The data were then normalised to the first PC 
score, using MATLAB 2013a (Natick, MA, USA).35,36 Spectra 
were acquired from 400 to 1800 cm−1, and this full spectral 
range was used for the data processing and analysis (see below).
Prediction model development
Prediction models were generated from paired toenail samples 
for increasing time periods between sample collection and 
onset of fracture (in the matched case). The smallest time 
period that could be investigated was up to 10 years due to the 
small number of samples available at shorter periods being 
insufficient to build useful models. Further periods increased 
by 1-year increments up to a maximum of 20 years. Within 
each increment, we aimed to assign approximately 75% to 
develop the model and withhold 25% to test the model. As 
each increment had relatively few samples, the rounding effect 
resulted in an overall 80/20 split in the development and test 
sets. For example, at 10 years, 14 case-control pairs were 
assigned to the development set and 5 pairs to the test set. The 
next 1-year increment added 4 pairs to the development set 
and 1 to the test set so that the total for the 11-year period was 
18 and 6, respectively. The counts at the maximum 20-year 
period were 67 and 15 pairs, respectively.
For each period, the spectra were subject to a principal com-
ponent analysis, whose scores were filtered by significance on a 
t test (between cases and controls) to reduce the dimensionality 
of the data. The 4 PC scores selected were then input into 
linear discrimination analysis (LDA) to develop a predictive 
multivariate statistical model.37 The data reduction and filter-
ing reduced the number of input variables for the LDA from 
776 to 4, reducing the risk of overfitting. For clarity, any refer-
ence to ‘scores’ in the article refer to the LDA discriminant 
scores unless indicated otherwise.
The Raman score and risk of hip fracture
In the test set of toenails, we examined the association between 
the Raman scores and the risk of hip fracture for increasing 
time periods in unconditional logistic regression models con-
trolled for age.
The performance of the Raman scores alone, the CRFs 
alone, and the score in combination with the CRFs were evalu-
ated. Only CRF data available at the time of the nail sample 
collection were used as inputs into the models to avoid biasing 
the analysis. Only the CRFs with an estimated (based on prev-
alence in the training set) 1 positive sample present in both 
groups in test set were included in the models. To compare the 
models which contain both continuous and categorical data, 
the data were standardised to a distribution with mean = 0 and 
SD = 1 and predictive values were generated by generalised lin-
ear model for a binomial reference variable (fracture vs non-
fracture). The odds ratio (OR) per 1 SD increase was used to 
evaluate the performance of the linear model.
Partial subtraction spectra
When comparing spectra, it is common to simply scale the 
spectra either to the mean intensity or to a standard peak. In 
complex spectra, neither solution is entirely satisfactory as the 
large number of overlapping bands can make the resulting dif-
ference spectrum difficult to interpret. As a visual aid, we have 
prepared partial subtraction spectra, where we have scaled the 
subtrahend such that the minuend has no negative peaks. This 
point is decided by subtracting until negative bands appear 
then reducing the scaling factor to the point just before any 
negative features are observed. We also show the traditional 
subtraction spectrum (spectra were already normalised as 
described above so no further scaling adjustment applied) in 
Figure 1 so that those more familiar with the traditional sub-
traction spectrum can compare.
Results
Characteristics of the study population
Characteristics of the hip fracture cases and controls at the 
time of toenail collection are shown in Table 1. As cases and 
controls were matched on month and year of birth, the mean 
age (58 years) was identical in both groups. None of the cases or 
controls had a diagnosis of rheumatoid arthritis when the toe-
nails were collected; therefore, this factor could not be consid-
ered in further analyses. About 99% of both cases and controls 
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were white, with 1 African American subject among the cases 
and 1 Asian subject among the controls. The cases had a higher 
number of smokers and thyroid hormone users, whereas con-
trols had a higher mean BMI and were more likely to report a 
diagnosis of osteoporosis and high alcohol intake.
Spectral analysis. Figure 1 illustrates the mean spectra grouped 
into case and control groups with an increment of 4 years 
between collection and fracture, with subtractions scaled to the 
point just before negative features appear in the spectra (plus 
the standard subtraction in black). These are superimposed on 
the equivalent spectra observed in our previous clinical study.13 
Our previous clinical study was comparing existing fracture 
(increment <0) and no samples available for this study had a 
delay shorter than 4 years, so these spectra represent those clos-
est to the conditions of this previous study.
The spectral features correspond well to the spectral fea-
tures identified in our previous studies,9–13 with the disulphide 
stretching mode 510 cm−1 very prominent in the non-fracture 
controls, whereas the fracture cases exhibit a weaker broader 
peak shifted to 525 cm−1. The fracture cases also exhibit a 
strong doublet at 625 and 645 cm−1, a pair of peaks characteris-
tics of free S-H bonds. In the amide I region, sensitive to pro-
tein secondary structure, the fracture cases exhibit elevated 
intensity around 1653 cm−1, whereas the non-fracture controls 
exhibit elevated intensity around 1660 cm−1.
Figure 2A shows the distribution of samples by increment 
between collection and occurrence of fracture. Most of the 
fractures occurred beyond 15 years after collection, with the 
mode being a fracture occurring between 17 and 18 years after 
collection. Figure 2B shows how the difference in mean Raman 
score between cases and controls varies with the time to frac-
ture. Between 4 and 8 years, the difference is relatively consist-
ent, but between 8 and 15 years, the contrast between cases and 
controls gradually declines. From 15 years and beyond a plateau 
is evident where the mean difference is 1/5 of the difference 
between 4 and 8 years.
Figure 3 compares average non-fracture and fracture spectra 
at the 2 plateaus in Figure 2B and in the middle of the slope. 
Many features consistently appear in the same set of donors, 
including the disulphide mode (510 cm−1), tyrosine modes (810 
and 830 cm−1), and the bands sensitive to secondary structure 
(amide I: 1630-1680 cm−1, amide III: 1220-1320 cm−1, and the 
C-C stretching modes: 920-1000 cm−1).
Statistical analysis: hip fracture prediction
The Raman score from hip fracture cases and controls up to 
20 years after toenail collection achieved an OR of 2.2 (95% 
confidence interval [CI]: 1.5-3.1) in the test set (Table 2). The 
OR based on the CRFs alone was similar, and the highest pre-
dictability was achieved for the Raman score and CRFs 
together (OR = 3.8, 95% CI: 2.6-5.4).
Results are also shown for Raman scores from hip cases and 
controls up to 13 years after toenail collection, a period that was 
selected because it represents the approximate midpoint of the 
Figure 1. Raman spectra for the Nurses’ Health Study 4-year fractures 
(dark red, dark green, and blue) compared with FRAN fractures (light 
green, bright red, and black). Most of the same features are visible. This 
is the shortest interval between collection and fracture so would be 
expected to be most similar to FRAN. FRAN indicates Fracture Risk 
Assessment by Nail.
Table 1. Clinical risk factor at time of toenail collection in hip fracture 
cases and controls in the Nurses’ Health Study.
CASES 
(N = 82)
CONTROLS 
(N = 81)
Agea, y (mean ± SD) 57.6 ± 3.2 57.6 ± 3.3
BMI, kg/m2 (mean ± SD) 24.4 ± 4.3 25.5 ± 4.6
Current smoker (n) 28 21
Osteoporosis (n) 2 4
Wrist fracture (n) 19 18
Rheumatoid arthritis (n) 0 0
Diabetes type 1 (n) 1 0
Age at menopause <45 y (n) 8 8
Thyroid hormone user (n) 16 5
≥3 alcoholic drinks/d (n) 1 3
White (n) 81 80
African American (n) 1 0
Asian (n) 0 1
aControls were matched to cases on month and year of birth.
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slope in Figure 2B and provided sufficient samples to create a 
representative model. The OR of 6.3 (95% CI: 3.0-12.6) was 
higher than for the 20-year period. In contrast, a model based 
on only the cases and controls beyond 13 years did not provide 
a predictive model, giving an OR = 2.1 (95% CI: 0.8-6.1). The 
CRFs did not contribute any benefit to the Raman score in the 
model up to 13 years.
Discussion
Anecdotally, patients diagnosed with osteoporosis have 
reported loss of fingernail resilience (D. Lyons, Personal 
Communication, April 2002) with disease progression. 
Previous studies by the authors have suggested a relationship 
between human nail structure, osteoporosis, and fracture risk, 
providing preliminary supporting evidence for a new bio-
marker.9–13 Taking advantage of archived nail samples from 
post-menopausal women 50 to 63 years of age, this study tested 
the ability of Raman spectroscopy of nail samples to identify 
hip fracture risk over periods of 4 to 20 years in age-matched 
cases and controls. We developed a predictive model using a 
subset of the study sample and tested the Raman model score 
in the remaining samples. We found that risk of hip fracture 
was more than double per 1 SD change in Raman score for the 
full 20-year period. We also demonstrated that the contrast 
between cases and controls improved as the period between 
collection and fracture shortens, such that risk was increased 
more than 6-fold when limited to a 13-year period after nail 
collection. This prediction period is in line with CRF-based 
tools such as FRAX and Q-fracture, which focus on predicting 
fractures up to 10 years in advance. The Raman score provided 
discriminatory power greater than the available CRFs, a com-
parable result to that seen with our retrospective data sourced 
from the 633 subjects in the FRAN study13 which suggests 
that the Raman-based score is providing new information and 
could provide a significant performance enhancement. Other 
methods have been investigated for assessing nails as predictors 
or osteoporosis and fracture risk, including laser-induced 
breakdown spectroscopy, which showed some correlation with 
BMD,38 and cation measurements, for which there have been 
conflicting reports.39,40
In perimenopausal women 45 to 54 years of age followed for 
an average of 10 years, Barr et al41 reported hazard ratios of 1.9 
(95% CI: 1.5-2.3) for osteoporotic fractures per 1 SD decrease 
in spine BMD and 1.8 (95% CI: 1.4-2.2) per 1 SD decrease in 
femoral neck BMD when measured by DXA. Most of the 
osteoporotic fractures in that population were wrist fractures, a 
less serious and costly outcome than the hip fractures assessed 
in this study. Results were similar in the subgroup with BMD 
measurements using quantitative ultrasound (QUS), and vari-
ous other studies have also demonstrated that QUS has a rela-
tive risk of fracture comparable with DXA-based measurements 
over short time frames.42–44 If similar results to those shown in 
this study are found when the Raman-based score is validated 
Figure 2. (A) Sample distribution by increment between collection and 
fracture. (B) Mean difference in Raman score for fracture vs non-fracture 
for donors with different increments between collection and fracture 
(predictions made using model derived from donors with fractures up to 
13 years after collection but applied to all data).
Figure 3. Scaled subtraction spectra of non-fractures and fractures at 
increments between collection and fracture occurrence (in age-matched 
sample for controls) of 4, 12, and 16 years. These increments represent 
points in Figure 2B at the 2 plateaus and the middle of the slope.
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in a larger independent sample, its performance in combination 
with CRFs would be at least comparable with those reported 
by Barr et al for DXA and QUS.
The use of archived nails for this type of analysis is based on 
the assumption that they do not substantially change from col-
lection at baseline, and this is valid according to the literature. 
A comparison of 500-year-old mummified baby nails showed 
little variation in key structures compared with the nails of 
modern-day babies.45 What differences did occur were attrib-
uted to changes in the hydration level of the keratin. The litera-
ture suggests that Raman spectra can be measured decades 
after the original sample was stored without degradation.46 
The nails in the NHS have been kept for more than 25 years in 
a manner consistent with these findings.
Collagen and keratin are fibrous proteins that serve structural 
and mechanical roles in the body, providing a framework for 
support of cells and tissues.47 Both proteins consist of polypep-
tide chains formed by amino acid condensation47 and express the 
same characteristic bands (CH2 and amide I) in key regions of 
Raman spectra collected from biological samples.11,47 Byproducts 
of bone remodelling are evident in serum and urine; therefore, it 
is conceivable that these markers of changes in bone chemistry 
could also be detected in nails, a continually growing material, 
more stable than serum and urine, which is in direct contact with 
the periosteum of the phalangeal bone during its growth.48
There have been calls to develop population-based screening 
protocols for osteoporosis and fracture risk that could be imple-
mented around time of the menopause so that earlier treatment 
could improve outcomes.1,41 In contrast to DXA or QUS, tests 
amenable to high-throughput testing by clinical reference labs 
could facilitate screening a broader population base in combina-
tion with CRF-based screening tools. A number of markers of 
bone resorption are offered as central lab tests including those 
based around hydroxyproline, hydroxylysine glycosides, pyridi-
noline, deoxypyridinoline, aminoterminal, carboxyterminal, 
etc,49,50 although to-date clinical studies have not provided 
information on the biochemical marker fracture prediction per-
formance in women less than 65 years with long follow-up peri-
ods. The simplicity of preparing, transporting, and testing nail 
clippings may enable central lab testing for fracture risk assess-
ment. A simple-to-use analysis, which could accurately identify 
high-risk women who would most benefit from increased mon-
itoring and treatment at an earlier stage, would be a significant 
public health advancement.
This preliminary study suggests that Raman spectroscopy 
of the human nail is a promising tool for identifying post-
menopausal women less than 65 years of age who are at 
increased risk of hip fracture over a period of up to 13 years. 
The preliminary results compare favourably with existing 
QUS, DXA, and CRF-based technologies and support the 
view that the prediction model provides a platform for a con-
firmatory study in an independent population to validate the 
prognostic marker. Further work is needed to validate the pre-
dictive ability of Raman spectroscopy for the assessment of 
future fracture risk.
Limitations of the study
1. Underpowered for reliably evaluating predictive perfor-
mance of Raman spectroscopy for periods up to 10 years 
after nail collection. This means that overall spectro-
scopic trends associated with variable period between 
collection and fracture can be examined and investigated 
but no confident assertions about predictive performance 
can be made.
2. Hip fractures were self-reported and no clinical (ie, 
X-ray or other radiographic) evidence was collected 
to validate the reports. However, all women in the 
cohort are nurses and should be capable of accurate 
reporting.
3. Difficult to compare the predictive power of CRFs that 
form part of FRAX when combined with the Raman 
score in isolation as all these CRFs were not assessed or 
in comparison with the previously published FRAN 
study, which used CRFs from QFracture.
4. The study used predominantly white women, so no con-
clusion can be made on the effect of race nor sex.
5. Further work to understand the underlying mechanism 
of action linking bone and nail is also required.
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Table 2. Prediction of hip fracture by Raman score and CRFa in the 
test set from the Nurses’ Health Study.
CASES/CONTROLS OR (95% CI)B
Total sample 15/14  
Raman score 2.2 (1.5–3.1)
CRF 2.0 (1.4–2.9)
Raman score + CRF 3.8 (2.6–5.4)
≤13 y to hip fracture 7/7  
Raman score 6.3 (3.0–13.1)
CRF only 1.9 (1.0–3.5)
Raman score + CRF 6.3 (3.0–13.1)
>13 y to hip fracture 8/7 2.14 (0.8–6.1)
Abbreviations: CI, confidence interval; CRF, clinical risk factor; OR, odds ratio.
a Clinical risk factors (assessed at toenail collection) included all factors with 
a minimum of 5 samples (body mass index, osteoporosis diagnosis, thyroid 
hormone user, and current smoker).
b OR in the test set and 95% CI for risk of hip fracture per 1 SD increase in 
standardised predicted values of factors in the model.
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